Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cream showdown: which works better for dark spots?

NCT ID NCT07327983

Disease control Sponsor: Gujranwala medical college District Headquarters Hospital, Gujranwala Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two creams—20% azelaic acid and 4% hydroquinone—on 146 adults with melasma, a condition causing dark patches on the face. Participants applied the cream daily for 12 weeks, and doctors tracked changes in patch size and color. The goal was to see which cream works better and if azelaic acid is a safe alternative to hydroquinone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

146 people

The number who actually took part.

Started

May 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with clinically diagnosed epidermal melasma confirmed by Wood's lamp examination * Male or female participants of any age * Willingness to provide written informed consent * Ability to comply with study procedures and follow-up visits Exclusion Criteria:- Dermal or mixed-type melasma * Active cutaneous or facial skin infection * History of keloid formation * Recent use of other topical or systemic depigmenting agents * Presence of photosensitive disorders * Pregnancy or lactation * Refusal or inability to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperpigmentation Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma Melasma (facial melasma)

Contacts and locations

Locations

  • Gujranwala Medical College Hospital

    Lahore, Punjab Province, +92, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.